From The Editor

  1. Edge AI Is Reshaping How Clinical Trials Run 3/12/2026

    Edge computing and AI are transforming clinical trials – enabling real time monitoring, decentralized research, and faster, more cost-effective drug development.

  2. Telehealth In Clinical Trials: What Sites And Patients Think 3/4/2026

    Sites and patients have complicated views on telehealth in trials. Here’s what the evidence shows about who benefits, who bears the burden, and where the limits are.

  3. Telehealth In Clinical Trials: What You Need To Know 2/26/2026

    Telehealth is a tool, not a trial design. Learn how televisits, ePRO, and remote monitoring fit into traditional, hybrid, and decentralized clinical trials.

  4. Forget More Clinical Tech, We Need More Adoption 2/23/2026

    At SCOPE Summit, Craig Lipset shared a blunt assessment of clinical trial innovation: the tools exist, regulators are engaged, and digital approaches offer clear quality advantages — yet adoption remains the industry’s biggest hurdle. From evolving FDA inspection expectations to the normalization (and lingering misconceptions) of decentralized trials, Lipset argues progress will depend less on new technology and more on scaling what already works.

  5. Joe Dustin: Sites Are Driving Clinical Tech Evolution 2/20/2026

    At SCOPE Summit 2026, Joe Dustin shared why clinical trial sites are emerging as the next drivers of innovation. As sites digitize operations and push back against the burden of sponsor-mandated systems, new models like “bring your own technology” and seamless digital data flow aim to reduce duplication, speed startup, and improve both coordinator and patient experiences.

  6. How Salk And Sabin Helped Create The Modern Clinical Trial 2/17/2026

    How Jonas Salk and Albert Sabin pioneered double-blind methodology, HeLa cell assays, and IBM data processing – innovations that became the global standard for clinical trials.

  7. Why HEOR Keeps Arriving Too Late — And How ClinOps Can Fix It 12/9/2025

    Rob Abbott, CEO of ISPOR, breaks down why HEOR timing keeps clashing with ClinOps timelines and offers practical ways to integrate value, evidence, and payer expectations much earlier in development.

  8. FDA Vs. MHRA Vs. EMA: Differences In Externally Controlled Trials 10/23/2025

    As the FDA, MHRA, and EMA release draft frameworks on externally controlled trials, sponsors face differing expectations. The U.K. leans pragmatic, the U.S. remains cautious, and Europe’s guidance is still evolving — leaving global trial planners to navigate regulatory gray zones.

  9. RWE Is Growing Up, And Here's Why That Matters 9/29/2025

    Real-world evidence is shifting from the margins to the mainstream of drug development, but data quality, trust, and regulatory clarity remain hurdles. ISPOR is helping set the standards to guide its future.

  10. The Dream Is EHR-To-EDC — eSource Is The Wake-Up Call 9/11/2025

    EHR-to-EDC integration promises efficiency but struggles with interoperability, compliance, and site adoption. eSource emerges as the real bridge, with case studies like MSK proving it can cut setup times, boost accuracy, and lighten site workload.